Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- Acronyms MYTHOS trial
- 20 Jan 2025 New trial record